Department of General and Hepato-Bbiliary Surgery, Liver Transplantation Service, Ghent University Hospital and Medical School, De Pintelaan 185, 2K12 IC, Ghent, 9000, Belgium.
Surg Endosc. 2011 Jan;25(1):79-87. doi: 10.1007/s00464-010-1133-8. Epub 2010 Jun 8.
Laparoscopic left lateral sectionectomy (LLS) has gained popularity in its use for benign and malignant tumors. This report describes the evolution of the authors' experience using laparoscopic LLS for different indications including living liver donation.
Between January 2004 and January 2009, 37 consecutive patients underwent laparoscopic LLS for benign, primary, and metastatic liver diseases, and for one case of living liver donation. Resection of malignant tumors was indicated for 19 (51%) of the 37 patients.
All but three patients (deceased due to metastatic cancer disease) are alive and well after a median follow-up period of 20 months (range, 8-46 months). Liver cell adenomas (72%) were the main indication among benign tumors, and colorectal liver metastases (84%) were the first indication of malignancy. One case of live liver donation was performed. Whereas 16 patients (43%) had undergone a previous abdominal surgery, 3 patients (8%) had LLS combined with bowel resection. The median operation time was of 195 min (range, 115-300 min), and the median blood loss was of 50 ml (range, 0-500 ml). Mild to severe steatosis was noted in 7 patients (19%) and aspecific portal inflammation in 11 patients (30%). A median free margin of 5 mm (range, 5-27 mm) was achieved for all cancer patients. The overall recurrence rate for colorectal liver metastases was of 44% (7 patients), but none recurred at the surgical margin. No conversion to laparotomy was recorded, and the overall morbidity rate was 8.1% (1 grade 1 and 2 grade 2 complications). The median hospital stay was 6 days (range, 2-10 days).
Laparoscopic LLS without portal clamping can be performed safely for cases of benign and malignant liver disease with minimal blood loss and overall morbidity, free resection margins, and a favorable outcome. As the ultimate step of the learning curve, laparoscopic LLS could be routinely proposed, potentially increasing the donor pool for living-related liver transplantation.
腹腔镜左外叶切除术(LLS)已广泛应用于治疗良性和恶性肿瘤。本报告描述了作者使用腹腔镜 LLS 治疗不同适应证的经验演变,包括活体肝移植供肝切除。
2004 年 1 月至 2009 年 1 月,37 例连续患者接受了腹腔镜 LLS 治疗良性、原发性和转移性肝脏疾病,其中 1 例为活体肝移植供肝切除。37 例患者中,19 例(51%)因恶性肿瘤行切除术。
除 3 例(因转移性癌症死亡)外,所有患者均存活且状况良好,中位随访时间为 20 个月(8-46 个月)。良性肿瘤中主要的适应证为肝细胞腺瘤(72%),恶性肿瘤中首先为结直肠肝转移(84%)。1 例活体肝移植供肝切除。16 例(43%)患者有既往腹部手术史,3 例(8%)患者接受了 LLS 联合肠切除术。中位手术时间为 195 分钟(115-300 分钟),中位出血量为 50 毫升(0-500 毫升)。7 例(19%)患者存在轻度至重度脂肪变性,11 例(30%)患者存在非特异性门脉炎症。所有癌症患者的切缘自由距离中位数为 5 毫米(5-27 毫米)。结直肠肝转移的总体复发率为 44%(7 例),但无肿瘤复发于手术切缘。无中转开腹,总发病率为 8.1%(1 级 1 例,2 级 2 例)。中位住院时间为 6 天(2-10 天)。
无门静脉阻断的腹腔镜 LLS 可安全用于治疗良性和恶性肝脏疾病,出血量少,总发病率低,切缘自由,预后良好。作为学习曲线的最后一步,腹腔镜 LLS 可以常规应用,可能增加活体肝移植供肝来源。